Merrion claimed that the agreement will evaluate the ability of its patented Gipet technology to enhance the compounds’ clinical profile and provide a substantially improved product.
On successful completion of the feasibility agreement, Merrion and Rebel Pharmaceuticals will enter into license agreements; the financial terms, including milestones and royalties, have already been agreed.
Merrion Pharmaceuticals CEO John Lynch said that they were pleased to be entering into this agreement with Rebel Pharmaceuticals and building a relationship with them.
"We believe there can be substantial patient benefits from improved oral formulations of these compounds using our Gipet technology," Lynch said.
Rebel Pharmaceuticals CEO David Blume said that they were excited to partner with Merrion Pharmaceuticals to use their Gipet technology to achieve their goals for these development programs of enhancing existing drugs to benefit patients.
Merrion claimed that its patented drug delivery technology, Gipet, is supported by a large database reflecting 10 years’ research and development by drug delivery experts and 21 clinical studies conducted on a broad range of drug types.
In a database comprising more than 40 compounds which have poor permeability, GIPET has shown the ability to improve absorption by as much as 200 times, achieving intersubject reproducibility and with a positive safety database.